A New Path to Drug Discovery
Bi-XDC technology empowers currently undruggable molecules and targets, transforming them into druggable entities. Designed to tackle substantial unmet medical needs in cancer and beyond, Bi-XDC offers a promising solution for advancing healthcare.
Coherent Biopharma
a company pioneering and developing Bi-targeting XDC technology
1 Proprietary Platform Technology
5+ First-in-Class Assets
15+ Global IP Protection
5+ Top scientists & industry experts.
110+ Expert professionals.
5 Potential First-in-Class
10+ Products
10+ Oncology Indication Clinical Trials
Integrated management organization in China, the U.S and Australia.
Breaking News
On October 18, 2023, Dr. Robert Huang, Founder, Chairman, and CEO of Coherent Biopharma, unveiled the latest clinical data on the company's leading pipeline product, CBP-1008, at the 14th World ADC Conference.
Coherent Biopharma announced today that their proprietary second-generation dual-ligand conjugate drug, CBP-1019, has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) on …
Coherent Biopharma announced that clinical data will be presented in the form of a poster at the 2023 European Society for Medical...